| Identification | Back Directory | [Name]
ASPERLIN | [CAS]
30387-51-0 | [Synonyms]
D02999
U 13933
ASPERLIN
ASPERLINE
Asperlin (usan)
D-galacto-Oct-2-enonic acid, 6,7-anhydro-2,3,8-trideoxy-, δ-lactone, 4-acetate | [Molecular Formula]
C10H12O5 | [MDL Number]
MFCD01939372 | [MOL File]
30387-51-0.mol | [Molecular Weight]
212.2 |
| Hazard Information | Back Directory | [Uses]
Antibacterial; antineoplastic. | [in vivo]
Asperlin (40-80 mg/kg; p.o.; once daily for 12 weeks) effectively prevents the development of obesity, stimulates energy expenditure and modulates gut microbiota in high-fat diet (HFD)-fed mice[2].
Asperlin (80mg / kg; p.o.; once daily for 12 weeks) remarkably suppresses atherosclerotic plaque formation in the aorta, as revealed by the reduced aortic dilatation and decreased atherosclerotic lesion area in high-fat diet (HFD)-fed ApoE-/- mice[5].
| Animal Model: | C57BL/6J mice (8-weeks old, weighing 20-25g) were fed with a high-fat diet (HFD) to induce obesity[2] | | Dosage: | 40, 80 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 12 weeks | | Result: | Showed lower body weight, and food intake was not varied.
Reduced the blood levels of total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL-c). Liver TC, TG contents and fat vacuoles were also substantially reversed.
Increased energy expenditure and enhanced thermogenic gene (PGC1α, UCP1, CIDEA, CPT1B, FATP1, CYTO-C) expression in adipose tissue.
Increased the diversity of the gut microbes. Significantly shifted the structure of the gut microbiota.
|
| Animal Model: | Male C57BL/6 J and C57BL/6 J ApoE-/- mice (6-8 weeks, weighting 20-25 g)[5] | | Dosage: | 80 mg/kg | | Administration: | Oral gavage (p.o.), once daily for 12 weeks | | Result: | Remarkably suppressed atherosclerotic plaque formation in aorta, reduced the white atherosclerotic lesions, effectively inhibited aortic dilatation in ApoE-/- mice. |
|
|
|